Overview
Clinical Benefits
- Pulsatile GH release
- Improved recovery and sleep
- Fat loss
- Lean muscle support
Administration
Subcutaneous injection — best on empty stomach or post-workout
Drug class: ghrh analog
Clinical Dosing
Typical dosage
100-200mcg per injection
Starting dose
100mcg
Cadence
1-3x daily (pre-bed most common)
Full titration schedule
| Phase | Dose |
|---|---|
| Weeks 1-2 | 100mcg once daily pre-bed |
| Weeks 3-8 | 100-200mcg 2-3x daily (morning, pre-workout, pre-bed) |
| Weeks 9-12 | Maintain — cycle off 4 weeks after 12 weeks |
Safety Profile
Side effects
- • Injection site redness
- • Transient flushing
- • Mild headache
- • Numbness/tingling
Contraindications
- • Active cancer
- • Pregnancy
- • Pituitary tumor
Do not combine with
Frequently asked questions
CJC-1295 (No DAC) / Mod GRF 1-29 is most commonly researched for: Pulsatile GH release, Improved recovery and sleep, Fat loss, Lean muscle support.
Ready to build a protocol with CJC-1295 (No DAC) / Mod GRF 1-29?
LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.
You’ll be asked to sign in first. Free tier includes the chat preview.
Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.